A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and …
The COVID-19 pandemic has created significant concern for everyone. Recent data from
many worldwide reports suggest that most infections are caused by the Omicron variant and …
many worldwide reports suggest that most infections are caused by the Omicron variant and …
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
L Yang, Z Wang - European journal of medicinal chemistry, 2023 - Elsevier
The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling …
Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19
J Hammond, RJ Fountaine, C Yunis… - … England Journal of …, 2024 - Mass Medical Soc
Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …
Oral Simnotrelvir for adult patients with mild-to-moderate covid-19
B Cao, Y Wang, H Lu, C Huang, Y Yang… - … England Journal of …, 2024 - Mass Medical Soc
Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study
S Dryden-Peterson, A Kim, AY Kim… - Annals of internal …, 2023 - acpjournals.org
Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …
[HTML][HTML] Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April–September 2022
MM Shah - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Among US adults diagnosed with COVID-19, including those with previous infection or
vaccination, persons who were prescribed Paxlovid within 5 days of diagnosis had a 51 …
vaccination, persons who were prescribed Paxlovid within 5 days of diagnosis had a 51 …
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a retrospective …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
[HTML][HTML] Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …